Acasti Pharma Announces the Closing of Over-Allotment Option for its Public Offering of Common Shares Biotech Investing
ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872 Pharmaceutical Investing
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients Pharmaceutical Investing
Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura Pharmaceutical Investing
Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients Biotech Investing
Nymox Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate Pharmaceutical Investing
AIT Therapeutics Announces Data From Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria Patients Pharmaceutical Investing
